CBD /

 

Loading...
Country's Decision or any other Communication (DEC)
  |  
BCH-DEC-ZM-113203-1   |   PDF   |   Print   |  
| 
|  Close
last updated: 21 Feb 2018
Amendment
No
General Information
Zambia
Application to conduct phase 2B clinical trial for HIV vaccine
EN
29 Sep 2017
No
Subject of the decision, notification, communication or declaration
  • Decision on Contained use of LMOs (Article 6.2)
LMO identification & risk assessment
  • BCH-LMO-SCBD-116157-1 Living Modified Organism ALVAC‐HIV Vaccine
    Sanofi Pasteur | Production of medical or pharmaceutical compounds (human or animal) (Vaccines)
Document on the decision, communication, notification or declaration

Quick links

About the BCH About the Cartagena Protocol Supplementary Protocol

Sign in Search records Submit records
Registries: LMO-Organism-Gene Country Profiles
National Report Analyzer

Forums BCH Announcements

Need help?

Knowledge Base FAQs UNEP eLearning Training Site

Contact us at: bch@cbd.int
BCH Biosafety Clearing-House
Subscribe to e-mail notifications
Subscribe to our newsletter